Pharmaceutical innovation increasingly relies on external partnerships, licensing and acquisitions, as large pharma looks beyond internal R&D to access promising new medicines and technologies and to offset expected revenue impact from the pending patent cliff. This panel will explore the key forces driving this shift and what pharmaceutical companies look for when evaluating potential partnering opportunities. Using Poolbeg Pharma’s POLB 001 programme as a real-world partnering opportunity, the discussion will examine how scientific and clinical evidence, intellectual property, commercial potential, market access and development strategy combine to create a compelling partner-ready asset. Bringing together perspectives from biotech leadership, healthcare investment banking and commercial strategy, the panel will provide practical insight into how opportunities are assessed, structured and valued. The session will give investors a clearer understanding of the evolving pharmaceutical partnering landscape and how biotech companies can build and realise value through successful partnerships with Poolbeg’s POLB 001 playing a central role. Ed Bowsher Freelance Journalist and Investor Jeremy Skillington CEO, Poolbeg Pharma Chris Grimes-Crompton Partner & Advisor, Acumentis Global Michiel Bröker Head Biopharma EMEA, UBS
